For those who are not on the mailing list:-This gives a bit more info re. announcement.
Dear HealthLinx supporter
Released today and attached for your information is the ASX announcement regarding the license agreement between HealthLinx and Sigma Aldrich for HealthLinx?s IgY technology.
IgY immunodepletion technology is used in proteomic research that involves the identification of proteins (and/or biomarkers) present in biological fluids, such as blood, and the determination of their roles in diagnosing and/or treating diseases. Proteomics technology is estimated to be valued at greater than US$1.5 billion and growing at more than 15% per annum to approximately US$2.9 billion by 2014 (BCC Research Report code BIO034B, June 2009). The IgY technology makes up part of this market.
HealthLinx will update its supporters as developments occur.
Kind regards
Rochelle Lade EA to Nick Gatsios, Managing Director
HealthLinx Ltd 576 Swan Street Richmond VIC 3121 Australia t: +613 9208 4200 | f: +613 9208 4201 | www.healthlinx.com.au
HTX Price at posting:
2.1¢ Sentiment: Hold Disclosure: Held
